Patterns of treatment and outcome of fulvestrant 500mg in postmenopausal women with hormone-positive (HR+)/Her2-negative (HER2-) metastatic breast cancer (MBC): a real life multicenter Italian experience

Authors :: Emma Pozzi
Federico Sottotetti
A. Gambaro
Cristina Teragni
Luca Licata
Raffaella Palumbo
A. Ferzi
Barbara Tagliaferri
Antonio Bernardo
Source :: Annals of Oncology. 27:vi82
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Oncology
medicine.medical_specialty
Postmenopausal women
Fulvestrant
business.industry
HER2 negative
Hematology
medicine.disease
Metastatic breast cancer
Internal medicine
medicine
business
medicine.drug
Hormone

Tools